AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02980224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OmegaD
Description: OmegaD Softgels
Study NCT02980224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Softgels
Study NCT02941627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Zti
Description: Cochlear implant
Study NCT02941627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro One
Description: Sound processor
Study NCT01262690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230901
Description: Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
Study NCT01262690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230901
Description: Single dose SC
Study NCT00337870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT
Description: Cognitive-Behavioral/Relaxation Intervention
Study NCT02453204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Study NCT00758199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
Study NCT00758199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin hydrochloride
Description: Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
Study NCT00758199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone Acetate
Description: Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
Study NCT04119518 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CSEM Pulse Watch
Description: Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.
Study NCT02456363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF alpha
Description: Depending on patient need to use different TNF alpha
Study NCT03104413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab administered as intravenous (IV) infusion.
Study NCT02237300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR based cue-exposure therapy
Description: Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
Study NCT02237300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional Cognitive-behavioral treatment
Description: Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
Study NCT04153864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Activation Treatment
Description: A manualized 6-8 session BA treatment delivered individually to each participant.
Study NCT04153864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment
Description: A manualized 6-8 session BA treatment delivered individually to each participant.
Study NCT01197404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 12-session group intervention including affect management training as well as sexual health skills training.
Study NCT01197404 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 12-session group intervention including health information on a variety of developmentally relevant health topics.
Study NCT00806559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Re-designed room
Description: In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
Study NCT00806559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control room
Description: This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
Study NCT02982343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falls management plus exercise training
Description: Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
Study NCT02982343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Falls management only
Description: Participants will undergo a session of falls management and education.
Study NCT01307215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20mLs of 0.5%
Study NCT01307215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30mLs of 0.33%
Study NCT01307215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 40mLs of 0.25%
Study NCT01661907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Epi-GA/PCEA
Description: An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.
Study NCT01661907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GA/PCIA
Description: General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
Study NCT03620227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
Study NCT02456363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs and sulfasalazine
Description: randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
Study NCT01081964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabofloxacin
Description: Zabofloxacin 400mg capsule once daily for 3 days
Study NCT01081964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500mg orally for 7 days
Study NCT01081964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabofloxacin 400mg
Description: Zabofloxacin 400mg orally for 5 days
Study NCT03072004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
Study NCT03072004 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LLLT
Description: That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group
Study NCT03386916 — intervention group
Intervention type: PROCEDURE
Intervention: CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer
Study NCT01485172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropinirole monotherapy
Description: ropinirole as monotherapy in Parkinson's disease
Study NCT03997877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Increase physical activity Balanced diet
Study NCT01485172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole monotherapy
Description: ropinirole as monotherapy in Parkinson's disease
Study NCT01485172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo monotherapy
Description: placebo as monotherapy in Parkinson's disease
Study NCT03997877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Increase physical activity Balanced diet
Study NCT02721069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL-1
Study NCT02549924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
Study NCT02549924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 500 mg 3 times daily with the first bite of each meal
Study NCT03883841 — intervention group
Intervention type: DRUG
Intervention: Iron Sucrose Solution for Injection
Description: intravenous infusion of iron sucrose
Study NCT01421355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
Study NCT03146299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLH vs LAVH
Description: TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more
Study NCT04279418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed functional foods supplementation
Description: In this project, taking the method of random, double blindness and control, participants in the mixed functional foods group will take functional foods with main compositions of ginsenoside, green tea polyphenols and marine collagen peptide for three months. After that, neuropsychological tests and neuroimaging biomarkers will be compared between functional food group and placebo group.
Study NCT04279418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this project, taking the method of random, double blindness and control, participants in the placebo group will take placebo for three months. After that, cognitive changes and neuroimaging biomarkers will be compared between functional food group and placebo group.
Study NCT01034748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF00299804
Description: Single 45 mg oral dose of radiolabelled PF-00299804
Study NCT02865707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synergy-1
Description: Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).
Study NCT02865707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is carbohydrate adsorbed in the small bowel.
Study NCT02433080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape-Up following cancer treatment
Description: The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention.
Study NCT03347955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural implantation group
Description: Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant
Study NCT03347955 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery
Description: Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
Study NCT02803983 — intervention group
Intervention type: PROCEDURE
Intervention: Pediatric hip plate
Description: Children were treated with pediatric hip plate.
Study NCT02803983 — intervention group
Intervention type: PROCEDURE
Intervention: Cannulated screw
Description: Children were treated with cannulated screw.
Study NCT03373396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
Study NCT00885222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS parameters setting
Description: DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
Study NCT02925884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gunnar OTC Glasses Condition
Description: Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
Study NCT00654433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD-101
Description: A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
Study NCT04154527 — intervention group
Intervention type: OTHER
Intervention: Pelvic Floor and Abdominal Exercises
Description: two repetitions of each exercise, during exhalation phase
Study NCT03620227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
Study NCT02627261 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samples and bone marrow aspirates will be collected
Description: Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
Study NCT02961101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
Study NCT02961101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
Study NCT02961101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
Study NCT02015962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous potassium chloride
Study NCT02015962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral potassium chloride
Study NCT01753648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
Study NCT01753648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDOCT
Description: total retinal blood flow (together with DVA), retinal blood velocities
Study NCT01753648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocular perfusion pressure
Description: Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
Study NCT01367951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical fixation
Description: * The fractures will be reduced and stabilized by use of plates and screws~* Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~* Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~* Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted.
Study NCT01050517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole + ivermectin + praziquantel
Description: albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
Study NCT01050517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole + ivermectin + (1 week later) praziquantel
Description: albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
Study NCT01956721 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise training,
Study NCT01956721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training,
Study NCT01956721 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy
Study NCT01956721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Study NCT02730013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Square Stepping Exercise
Description: Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
Study NCT03293368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
Study NCT03293368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
Study NCT05178719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMA-zeolite
Description: given for a total period of 4 years
Study NCT04680182 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction drain
Description: Suction drain either kept for three weeks or gradually pulled out.
Study NCT04680182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction drain
Description: Suction drain either kept for three weeks or gradually pulled out.
Study NCT00629889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.
Study NCT00629889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study.
Study NCT01932437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: monoclonal antibody
Study NCT01932437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204
Study NCT03620227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.